Eli Lilly Surpasses $1 Trillion Market Cap with 60% U.S. Incretin Market Share
Analyst deep-dive into Lilly's position as healthcare's most valuable company, with ~60% U.S. incretin market share driven by tirzepatide and a retatrutide pipeline showing ~30% weight loss potential.